We hypothesize that CYP4F22 overexpression may function to regulate the accumulation of pro-apoptotic sphingolipids (e.g. ceramide) in cancer cells, which similar to RBM11, promote alternative splicing of the BCL-XS splice variant [54, 55]. Here, CYP4F22 is linked to cancer.